Industry Insights
Harnessing Human Skin Models for Drug Development
Industry InsightWe recently spoke with Pascal Descargues, CEO at Genoskin to learn more about the legal restrictions on animal testing and how human skin tissue can be used as an alternative.
Read More
Progress in Companion Diagnostic Development for Low-Grade Glioma
Industry InsightTo learn about the benefits of accelerating turnaround times for genomic testing and the importance of partnering with pharma companies to develop companion diagnostics, Technology Networks spoke with Luca Quagliata, PhD, BCMAS, Global Director of Medical Affairs for Thermo Fisher Scientific.
Read More
The Science Behind Saliva-Based Rapid Diagnostic Testing
Industry InsightHere, Dr Pretorius examines the use of saliva, rather than blood, in rapid diagnostic tests for malaria and how this clinically informative biofluid could help to improve healthcare in the world’s poorest regions.
Read More
New RNA Extraction Strategies Help Mitigate Shortages in SARS-CoV-2 PCR Components
Industry InsightAs the world continues to battle through the pandemic, developing innovative strategies to expand the availability of extraction, and any other testing components that are facing supply issues, will be an ongoing requirement.
Read More
Exploring the Technology Behind a Blood Test for Alzheimer's Disease
Industry InsightTechnology Networks recently spoke to Quanterix's Kevin Hrusovsky to hear more about how the company's technology is being applied in the pursuit of a biomarker for Alzheimer's disease, a progressive neurodegenerative condition for which diagnosis often occurs after the onset of symptoms.
Read More
Breaking Down Barriers in Proteomic-Based Drug Discovery
Industry InsightSomaLogic recently announced an agreement with the biopharmaceutical company Amgen that aims to advance Amgen's drug discovery and development programs through comprehensive proteomic profiling. We spoke with Roy Smythe to discover what barriers have been holding proteome analysis back, and how the collaboration with Amgen aims to change the landscape of drug discovery.
Read More
Biomaterial-Based Vaccine That Sits Under the Skin Shows Promise Against SARS-CoV-2
Industry InsightA team of multidisciplinary scientists – including bioengineers, materials-scientists and immunologists – at the Wyss Institute has created a novel infection vaccine platform know as OmniVax. Technology Networks spoke with Lead Senior Staff Scientist Ed Doherty from the Wyss Institute for Biologically Inspired Engineering at Harvard University, to learn more.
Targeting “Undruggable” Proteins by Selectively Controlling mRNA Translation
Industry InsightUp to 80% of proteins do not possess binding sites suitable for direct binding of small molecule drugs, making them “undruggable”. To overcome this problem, Anima Biotech has developed a platform to identify drugs with the ability to interfere with the production of these “undruggable” proteins, by selectively inhibiting the translation of mRNA.
Read More
Scripps Research Spin-Off Ushers a "New Era" in Vaccinology With Platform Technology
Industry InsightScripps Research spin-off company Ufovax employs the single-component self-assembling protein nanoparticle (1c-SApNP®) platform technology, that was created in the laboratory of Professor Jiang Zhu, to address some of the key challenges in modern vaccine development. We spoke with Dr Colette Saccomanno to learn more.
Read More
Towards a Deeper Understanding of the Proteomic Landscape
Industry InsightAt a recent London Proteomics Discussion Group Meeting, Professor Roman Fischer kicked off the event by addressing the apparent "failure" of proteomics to deliver new clinical biomarkers thus far. Technology Networks sat down with Fischer to discuss spatial proteomics, and to expand on some of the key aspects of his research.
Read More
